Vical Joins Forces With Astellas On CMV Vaccine
This article was originally published in The Pink Sheet Daily
Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.
You may also be interested in...
CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.
Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.